ClinicalTrials.gg
TerminatedNCT05316467Updated Jun 4, 2026

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

A Phase 2/3 interventional study of Intensive Lifestyle Intervention (ILI) and Megestrol Acetate 160 MG Oral Tablet in Endometrial Carcinoma, Obese and Overweight, sponsored by Xiaojun Chen. Terminated at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Xiaojun Chen · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
no enough enrolled patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Megestrol Acetate in Endometrial Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Megestrol Acetate · Endometrial Neoplasms.

Started
2022
with 1 other
Phase 2/3
2 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Xiaojun Chen

Among the 10 studies testing Megestrol Acetate in Endometrial Neoplasms, this one is one of 2 that started in 2022, is one of 2 in phase 2/3, and was the 7th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

2 of the 10 studies testing Megestrol Acetate in Endometrial Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Megestrol Acetate in Endometrial Neoplasms, or all of them as a file.
02

Study summary

To investigate the efficacy of weight management plus megestrol acetate in obese patients with early endometrioid carcinoma(EEC)asking for fertility-sparing treatment

Read the detailed description

Background:

High-dosage high-efficacy progesterone, such as Megestrol Acetate (MA) and medroxyprogesterone acetate(MPA), is still the first-line treatment for women with early endometrioid endometrial cancer (EEC) who want to preserve fertility. Approximately 70% to 80% of females who meet the criteria for conservation treatment are able to achieve CR after progestin therapy, with a median time of 6-7 months, but about 20% to 30% of patients get no response or need to take longer time to achieve remission (over one year). Overweight/obesity is an independent risk factor for fertility-sparing treatment response and pregnant outcomes in young females with early endometrioid cancer, substantial evidence showed that obesity can cause relatively lower complete response(CR)rates, longer time to achieve completer remission and lower birth rates besides metabolic disorders and other adverse effects caused by obesity. Weight management has been found to improve metabolic disorders, ovarian functions and pregnant outcomes.The hypothesize is that weight management plus progestin therapy may raise CR rates and pregnant outcomes in young female EEC patients asking for fertility conservation. Previous research has shown that metformin plus MA can increase CR rates. Enhanced lifestyle management (diet control, exercise and daily behavioral guidance) may improve metabolic conditions, increase CR rates and pregnant outcomes in obese EEC patients who want to preserve fertility. Till now, no similar studies were found, so the investigators design this study to explore the efficacy of weight control in EEC fertility-sparing patients to provide new evidence for improving conservative treatment.

Objective: To investigate whether weight management plus MA improve the efficacy of preserving fertility when compared to MA alone in obese women with EEC who want fertility conservation.

Design: This study is two single-arm, prospective, open-label. Patients with early-stage endometrioid carcinoma requiring conservation treatment with BMI ≥ 24 kg/m2 will be recruited in this study and they will be divided into two arms, one is overweight group (24kg/m2≤BMI\<28kg/m2) and another is obese group (BMI≥28kg/m2). Each arm and its sample size was designed according to Simon's Two-Stage Design. All enrolled patients will receive enhanced lifestyle management to control weight and take MA for treating EEC. Hysteroscopic examination, metabolic and inflammatory indicators will be performed every 12 to16 weeks while other indexes will be evaluated every month, including weight, heart rates,blood pressure and so on.For the progestin efficacy evaluation, CR is defined as the remission of EEC to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia with or without atypia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as disease progression in patients. Two months' maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.

Outcomes: Primary outcome is the CR rates of the two arms (overweight and obesity group). Secondary outcomes include pregnancy rates, live birth rates, weight loss, insulin resistance, chronic inflammation indicators, time to achieve CR and the recurrence rates and so on. Safety and side events during the whole trial will be monitored in two years.

03

Conditions studied

  • Endometrial Carcinoma
  • Obese
  • Overweight
  • Fertility Issues
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years≤age≤45years
  2. (body mass index) ≥24kg/m2
  3. Consent informed and signed
  4. confirmed as endometrial carcinoma Patients with endometrial specimens obtained by endometrial , diagnostic curettage or hysteroscopy and diagnosed histologically as endometrioid carcinoma, G1. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.
  5. Imaging Assessment Enhanced MRI of the pelvis and enhanced CT of the upper abdomen must be performed in 2 weeks prior to starting treatment to assess the lesions confined to the endometrial layer without clear myometrial infiltration or extrauterine involvement.
  6. Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.
  7. Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.

Exclusion criteria

Exclusion Criteria:

  1. Patients with non-endometrioid endometrial carcinoma, endometrioid endometrial carcinoma G2/G3 or other malignant tumors of the reproductive system; imaging suggests myometrial invasion, cervical involvement or extra-uterine involvement.
  2. Combined with severe medical disease or liver or kidney dysfunction: (ALT) or aspartate aminotransferase (AST) levels elevate to 3 times or more of the , kidney dysfunction ( \<30 mL/min)
  3. Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone.
  4. Those who have received high doses of high potency progestin or oral within the last 3 months (or those on maintenance medication).
  5. Those who require hysterectomy or other methods other than conservative treatment.
  6. Known or suspected pregnancy.
  7. Those who has to use progestin.
  8. Deep vein thrombosis, stroke, myocardial infarction.
  9. Severe joint lesions that prevent walking or movement.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    overweight 24kg/m2≤BMI<28kg/m2

    MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management

    Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Megestrol Acetate 160 MG Oral Tablet

  • Experimental
    BMI≥28kg/m2

    MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management

    Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Megestrol Acetate 160 MG Oral Tablet

Interventions

  • BehavioralIntensive Lifestyle Intervention (ILI)

    * dietary guidance * exercise guidance * lifestyle intervention

    Also known as: Weight Management

  • DrugMegestrol AcetateStudies of Megestrol AcetateMegestrol Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    enrolled participants will take Megestrol Acetate 160mg daily

    Also known as: yilizhi

06

What researchers measure

Primary outcomes

  1. Pathological complete response (CR) rates

    The 28-week CR rates will be calculated in two arms

    Time frame: From date of recruitment until the date of CR, assessed up to 28 weeks.

Secondary outcomes

  1. Pregnancy outcomes

    For patients have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period.

    Time frame: up to 2 years after complete response of the last participant

  2. Weight change

    Body weight will be recorded every month and compare its change during the trial in kilograms.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  3. Change of body composition

    Assess the improvement of body composition, the investigators will detect body composition with InBody machine and calculate changes of the indicated indexes.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  4. Change of heart rates

    Record heart rates in bpm (beats per minute) every 12-16 weeks and calculate its change during the trial.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  5. Change of blood pressures

    Record blood pressure (both of systolic and diastolic pressures) every 12-16 weeks and compare its change during the treatment.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  6. Blood glucose change

    Assess fasting glucose levels each 3 to 4 months and calculate changes during the trial in mmol/L.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  7. Blood lipids change

    Assess blood lipids levels each 3 to 4 months and compare their change during the treatment.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  8. Insulin resistance change

    Assess fasting insulin levels each 3 to 4 months and compare their changes during the trial.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  9. Ovarian reserve function change

    Detect serum Anti-Mullerian Hormone (AMH) levels each 3 or 4 months and calculate its change.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  10. Quality of life change

    Collect quality of life questionnaire (SF-36 and IWQOL-LITE) every 12-16 weeks and count scores.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  11. Physical activities change

    Collect physical activities questionnaire(IPAQ)and compare scores changes through conservative treatment.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  12. Chronic inflammatory indexes change

    Detect chronic inflammatory indexes, including TNF-α(tumor necrosis factor), IL-1 and IL-6, and calculate changes through the whole treatment period.

    Time frame: From date of recruitment, assessed up to 28 weeks.

  13. Time of pathological complete response (CR)

    Time of histologic regression from EC to proliferative or secretory endometrium

    Time frame: From date of recruitment until the date of CR, assessed up to 2 years.

  14. Incidence of adverse events

    Adverse events related with MA and weight control. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.

    Time frame: From date of recruitment until the date of CR, assessed up to 2 years.

  15. Relapse rates

    All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then the investigators can get the relapse rates. Comparison will be performed between two groups.

    Time frame: up to 2 years after the treatment for each patient

07

Study locations

1 site
  • Obstetrics and Gynecology Hospital, Fudan University
    Shanghai, Shanghai Municipality 200011, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Feb 2026, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Apr 7, 2022
StartActual
May 1, 2022
Primary completionActual
Feb 28, 2026
CompletionActual
Feb 28, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05316467
Lead sponsor
Xiaojun Chen
Responsible party
Xiaojun Chen (MD.PhD. Vice president of Obstetrics & Gynecology Hospital of Fudan University, Fudan University) — Sponsor-investigator
First posted
Apr 7, 2022
Start date
May 1, 2022
Primary completion
Feb 28, 2026
Completion
Feb 28, 2026
Last update
Jun 4, 2026

Study contacts

XIAOJUN CHEN, PhD
principal investigator · Obstetrics & Gynecology Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion